StockTipsArenaBeta

BUY Mankind Pharma Limited — Ashish Bahety, Profitmart Securities

BUYMankind Pharma Limited

byAshish Bahety, Profitmart SecuritiesHorizon: NA (inferred Swing (≤2wk))2 Sept 2026via CNBC Awaaz.

Entry₹2,365.2Inferred
Target₹2,450
Total upside +3.59%
Stop lossNot given
CMP₹2,3181h ago
Active-2.00%+5.69%upside left 9d left
Follow Ashish Bahety for new calls(34% target hit, 207 closed calls)Get alertsWatch MANKIND for new buy/sell callsGet alertsSee 99 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 5:52 pm IST
6 supporting1 neutral0 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·7 Sept · today

Elara initiates coverage on Alkem, Eris, IPCA and Mankind. Check ratings and targets

NewsEt-Markets·28 Aug · 1w ago

(opens in new tab)

Mankind Pharma inks exclusive deal for two insulin analogues in India

NewsCnbc-Tv18·20 Aug · 3w ago

(opens in new tab)

Mankind Pharma has entered into an exclusive in-licensing agreement for Insulin Degludec and its combination for the Indian market. This strategic move aims to expand the company's product portfolio i

NSE · Press Release·20 Aug · 3w ago

(opens in new tab)

Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. for Insulin Degludec and Insulin Degludec + Aspart Combination in In

BSE · Company Update·20 Aug · 3w ago

(opens in new tab)
Neutral / worth noting (1)

Mankind Pharma Limited's Board approved the integration of its wholly owned subsidiary, Bharat Serums and Vaccines Limited, into the company via voluntary liquidation.

NSE · Outcome of Board Meeting·26 Aug · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.